Company Filing History:
Years Active: 2017
Title: Patricia Bourne: Innovator in Antibody Development
Introduction
Patricia Bourne is a prominent inventor based in Palo Alto, CA, known for her significant contributions to the field of immunology. She has developed innovative solutions that enhance the understanding and treatment of various diseases through her work on antibodies.
Latest Patents
Patricia Bourne holds a patent for "Antibodies that bind to human programmed death ligand 1 (PD-L1)." This patent provides isolated antibodies that specifically bind to human PD-L1, along with antigen binding fragments of these antibodies. The disclosure includes kits comprising the anti-PD-L1 antibodies or binding fragments, along with a set of reagents for detecting a complex of the antibody bound to human PD-L1. These antibodies and fragments are crucial for the immunohistochemical detection of human PD-L1 expression in tissue samples. Additionally, the patent covers nucleic acid molecules encoding the antibodies and fragments, as well as expression vectors and host cells for their expression.
Career Highlights
Patricia Bourne has made significant strides in her career, particularly through her work at Merck Sharp & Dohme Corporation. Her innovative research has led to advancements in the field of antibody development, contributing to the understanding of immune responses and potential therapeutic applications.
Collaborations
Throughout her career, Patricia has collaborated with notable colleagues, including Robert H. Pierce and Linda Liang. These collaborations have fostered a productive environment for research and development, leading to impactful innovations in the field.
Conclusion
Patricia Bourne's work exemplifies the importance of innovation in the field of immunology. Her contributions, particularly in the development of antibodies targeting PD-L1, have the potential to significantly impact medical research and treatment strategies.